focus -WSS

focus

author：leisure time 2025-09-30 12:16:55 - browse：91

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Naloxone nonprofit donates 200,000 doses after FDA approval

focus

hotspot

WSS

What to know about Virgin Galactic's 1st mission taking paying customers to space

NYU Langone launches private ChatGPT for its health care data

Wegovy trial has doctors encouraged over new possibilities

What to know about Virgin Galactic's 1st mission taking paying customers to space

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

hotspot

focus

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Feds fine Medicare Advantage plans for overcharging members

Anesthesiologist group: stop taking Ozempic before surgery

American woman, child freed after being kidnapped in Haiti last month

Psychedelics group wrestles with new pharma identity

FDA panel issues narrow recommendation for Covid vaccine booster doses

State Dept. review finds Biden bears some blame for Afghanistan failures

In same hospitals, Black patients receive fewer opioids than white patients

As demand for Covid shots wanes, Moderna seeks its next success

What AAP's gender

Wikipedia

NIH trials fail to test meaningful long Covid therapies, experts say

Police still searching for prisoner who escaped from NYC hospital

Anavex keeps shifting the goalposts in its clinical trials

Appeals court upholds limits to abortion pill

The best solution to the drug shortages problem

Drastic changes should bring profitability, startup health insurers say

focus

hotspot

hotspot

knowledge